bicalutamide 150mg tablets
torrent pharma (uk) ltd - bicalutamide - oral tablet - 150mg
bicalutamide 150mg tablets
mawdsley-brooks & company ltd - bicalutamide - oral tablet - 150mg
bicalutamide tablet, film coated
zydus lifesciences limited - bicalutamide (unii: a0z3nau9dp) (bicalutamide - unii:a0z3nau9dp) - bicalutamide 50 mg - bicalutamide tablets 50 mg daily is indicated for use in combination therapy with a luteinizing hormone-releasing hormone (lhrh) analog for the treatment of stage d2 metastatic carcinoma of the prostate. bicalutamide tablets 150 mg daily is not approved for use alone or with other treatments [see clinical studies (14.2)]. bicalutamide is contraindicated in: hypersensitivity bicalutamide is contraindicated in any patient who has shown a hypersensitivity reaction to the drug or any of the tablet's components. hypersensitivity reactions including angioneurotic edema and urticaria have been reported. women bicalutamide has no indication for women, and should not be used in this population. pregnancy bicalutamide can cause fetal harm when administered to a pregnant woman. [see use in specific populations (8.1) ]. risk summary bicalutamide is contraindicated for use in pregnant women because it can cause fetal harm. bicalutamide is not indicated for use in females. there are no human data on the use of bicalutam
bicalutamide 150mg tablets
relonchem ltd - bicalutamide - oral tablet - 150mg
bicalutamide 150mg tablets
zentiva pharma uk ltd - bicalutamide - oral tablet - 150mg
bicalutamide tablet
major pharmaceuticals - bicalutamide (unii: a0z3nau9dp) (bicalutamide - unii:a0z3nau9dp) - bicalutamide 50 mg - bicalutamide tablets 50 mg daily is indicated for use in combination therapy with a luteinizing hormone-releasing hormone (lhrh) analog for the treatment of stage d 2 metastatic carcinoma of the prostate. bicalutamide tablets 150 mg daily is not approved for use alone or with other treatments [see clinical studies (14.2)]. bicalutamide is contraindicated in: bicalutamide is contraindicated in any patient who has shown a hypersensitivity reaction to the drug or any of the tablet’s components. hypersensitivity reactions including angioneurotic edema and urticaria have been reported. bicalutamide has no indication for women, and should not be used in this population. bicalutamide can cause fetal harm when administered to a pregnant woman [see use in specific populations (8.1)]. risk summary bicalutamide is contraindicated for use in pregnant women because it c
bicalutamide an bicalutamide 50mg film-coated tablet blister pack
juno pharmaceuticals pty ltd - bicalutamide -
bicalutamide accord healthcare 50 mg film-coat. tabl.
accord healthcare b.v. - bicalutamide 50 mg - film-coated tablet - 50 mg - bicalutamide 50 mg - bicalutamide
bicalutamide eg 50 mg film-coat. tabl.
eg sa-nv - bicalutamide 50 mg - film-coated tablet - 50 mg - bicalutamide 50 mg - bicalutamide
bicalutamide sandoz 50 mg (sandoz) film-coat. tabl.
sandoz sa-nv - bicalutamide 50 mg - film-coated tablet - 50 mg - bicalutamide 50 mg - bicalutamide